Fuzeon Gets Full Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche/Trimeris' HIV agent Fuzeon (enfuvirtide) has been granted full approval, the companies announced Oct. 15
You may also be interested in...
Roche/Trimeris’ Fuzeon Cited By FDA For Promotions At Scientific Conference
FDA letter cites claims made by Roche sales rep at last fall’s ICAAC, including that the injectable HIV therapy is “better than oral HIV drugs.” Rep also claimed that the drugs “confers ‘100% antiviral activity,’” FDA says.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.